Orexin neurons (also known as hypocretin neurons) are specialized hypothalamic neurons that produce orexin-A and orexin-B (hypocretin-1 and hypocretin-2) neuropeptides. These neurons are critical for wakefulness, arousal, and energy homeostasis. The selective loss of orexin neurons is the hallmark pathology of narcolepsy with cataplexy, and orexin system dysfunction has been implicated in Alzheimer disease, Parkinson disease, and other neurodegenerative conditions. [1]
| Property | Value | [2]
|----------|-------| [3]
| Category | Hypothalamus | [4]
| Location | Lateral hypothalamus, perifornical region | [5]
| Cell Type | Orexin/hypocretin neurons | [6]
| Neuropeptides | Orexin-A (hypocretin-1), orexin-B (hypocretin-2) | [7]
| Receptors | OX1R (HCRTR1), OX2R (HCRTR2) | [8]
Orexin-A (hypocretin-1): 33 amino acid peptide, orexin-B (hypocretin-2): 28 amino acid peptide. Both are derived from the same precursor, prepro-orexin (PPO), encoded by the HCRT gene. [9]
Orexin neurons co-express dynorphin as a co-transmitter involved in reward and pain, glutamate as an excitatory co-transmitter, nesfatin-1 as a satiety peptide, and neuronal activity-regulated pentraxin (NPTX2) for synaptic plasticity 1. [10]
Orexin neurons are the wake-sleep switch that maintains arousal. The ascending arousal system includes projections to the tuberomammillary nucleus (TMN) for histaminergic wake-promoting neurons, the locus coeruleus for noradrenergic wake neurons, the raphe nuclei for serotonergic neurons, and the basal forebrain for cholinergic arousal neurons. [11]
Orexin neurons stabilize wakefulness by preventing inappropriate sleep transitions through providing tonic excitatory input to arousal centers. They fire during active wake, reduce firing during NREM sleep, and virtually cease during REM sleep 2.
Orexin neurons integrate metabolic state with arousal. They respond to blood glucose levels through glucose sensing, leptin inhibits orexin neurons, and ghrelin stimulates orexin neurons. This ensures adequate food-seeking behavior during wakefulness.
Orexin system participates in reward processing. Activation of orexin neurons drives motivated behavior, the system is involved in drug seeking and addiction, and it links arousal with reward valence 3.
The hallmark pathology is selective loss of orexin neurons. Pathological findings include 85-95 percent reduction in orexin neurons in postmortem brains and reduced orexin-A in cerebrospinal fluid (below 110 pg/ml) 4. The immunological basis involves T-cell mediated destruction of orexin neurons, association with HLA-DQB1*06:02, and post-H1N1 influenza vaccination association 5. Clinical features include excessive daytime sleepiness (EDS), cataplexy (emotion-triggered muscle paralysis), sleep paralysis, and hypnagogic hallucinations.
Orexin system dysfunction in AD: Sleep disturbances are common with AD patients having orexin dysregulation. Increased orexin neuron activity may contribute to sleep fragmentation, there is elevated orexin-A in CSF of AD patients, and this correlates with nighttime agitation and sundowning 6. The amyloid relationship shows orexin may increase amyloid-beta production and sleep disruption increases amyloid burden in a bidirectional relationship 7. Orexin modulates cognition as hippocampal orexin signaling affects memory consolidation with therapeutic potential of orexin modulation in AD.
Orexin abnormalities in PD: Sleep disorders in PD involve orexin system changes. There is reduced orexin-A in CSF of PD patients with sleep disorders, loss of orexin neurons in PD with REM sleep behavior disorder, and this correlates with excessive daytime sleepiness 8. Neurodegeneration shows orexin neurons may be vulnerable as alpha-synuclein pathology can affect orexin neurons and Lewy bodies are found in the orexin region, contributing to non-motor symptoms. Motor connections involve basal ganglia orexin signaling that modulates dopaminergic neuron activity and may affect levodopa response with potential for therapeutic targeting 9.
Dementia with Lewy Bodies (DLB): Orexin neuron loss correlates with severity and is associated with sleep disturbance severity 10.
Multiple System Atrophy (MSA): Orexin dysfunction contributes to sleep disorders and may affect autonomic function.
Dayvigo (lemborexant) is a dual orexin receptor antagonist for insomnia that promotes sleep by blocking orexin signaling. Emerging agonists are being developed including orexin receptor agonists to replace lost orexin signaling that may improve wakefulness in narcolepsy and have potential for AD/PD sleep disorders.
These are used for insomnia including suvorexant (Belsomra), lemborexant (Dayvigo), and daridorexant (Quviviq). Paradoxically, blocking orexin can treat insomnia by reducing hyperarousal.
Orexin gene therapy involves experimental approaches to express orexin in remaining neurons or transplant cells. iPSC-derived orexin neurons offer potential cell replacement therapy for narcolepsy 11.
Modafinil is first-line for narcolepsy EDS with unknown orexin mechanism. Sodium oxybate is for cataplexy and EDS and may affect sleep architecture. Lifestyle modifications include scheduled naps, sleep hygiene, and avoiding trigger emotions.
The study of Hypothalamic Orexin Neurons In Narcolepsy has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.